ImmunoGen Announces Virtual 2020 Annual Meeting of Shareholders

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the 2020 Annual Meeting of Shareholders (the Annual Meeting) will be held virtually due to the public health impact of the coronavirus outbreak (COVID-19) and to support the health and well-being of the Companys management, shareholders, and other meeting participants.

The Annual Meeting will be held on Wednesday, June 17, 2020 at 9:00 a.m. Eastern in a virtual format only. As described in the proxy materials for the Annual Meeting previously distributed, shareholders as of the close of business on April 13, 2020, the record date, are entitled to participate in the Annual Meeting. Shareholders who attend the virtual Annual Meeting by following the instructions below will have an opportunity to vote and to submit questions electronically during the meeting.

Shareholders will not be able to attend the Annual Meeting in person. Instead, shareholders can attend the Annual Meeting by accessing the meeting center at www.virtualshareholdermeeting.com/IMGN2020.

  • Shareholders of Record: Shareholders of record at the close of business on April 13, 2020 (i.e., shares are held in the shareholders own name in the records of the Companys transfer agent, Broadridge Corporate Issuer Solutions, Inc. (Broadridge)) can attend the virtual Annual Meeting by accessing the meeting center at www.virtualshareholdermeeting.com/IMGN2020 and entering the 16-digit control number on the proxy card or Notice Regarding the Availability of Proxy Materials previously received. Shareholders of record that have misplaced their control number can call Broadridge at (855) 697-4961.
  • Beneficial Owners: Beneficial owners of the Companys common stock at the close of business on April 13, 2020 (i.e., shares are held by the shareholders broker in street name) can attend the Annual Meeting by accessing the meeting center at www.virtualshareholdermeeting.com/IMGN2020 and entering the 16-digit control number found on the notice and instructions received from their broker or other nominee.

If a shareholder does not have their 16-digit control number, the shareholder will be able to access and listen to the Annual Meeting as a guest, but the shareholder will not be able to vote their shares or submit questions during the Annual Meeting.

Instructions on how to connect to the Annual Meeting and participate via the Internet, including how to demonstrate proof of stock ownership, ask questions, and vote, are posted at www.virtualshareholdermeeting.com/IMGN2020.

Shareholders will also be able to submit questions through the platform being used for the Annual Meeting. Shareholders may ask questions that are confined to matters properly presented at the Annual Meeting and of general concern to the Company.

The Annual Meeting will begin promptly at 9:00 a.m. Eastern on June 17, 2020. Shareholders are encouraged to access the Annual Meeting prior to the start time. Online access will open approximately at 8:45 a.m. Eastern, and shareholders should allow ample time to log in to the Annual Meeting and test their computer audio system. The Company recommends that shareholders carefully review in advance the procedures needed to gain admission to the Annual Meeting.

Whether or not a shareholder plans to attend the Annual Meeting, the Company urges shareholders to vote and submit their proxy in advance of the Annual Meeting by one of the methods described in the proxy materials for the Annual Meeting.

A notice regarding this change to a virtual meeting format (the Notice) is being filed with the Securities and Exchange Commission together with this press release. Additional information regarding the Annual Meeting, shareholder participation and voting is provided in the Notice, which all shareholders are urged to read.

Technical Difficulties

If shareholders encounter any difficulties accessing the virtual meeting during the check-in or meeting time, please call the technical support number that will be posted on the virtual Annual Meeting log in page.

The virtual Annual Meeting platform is fully supported across browsers (Internet Explorer, Firefox, Chrome, and Safari) and devices (desktops, laptops, tablets, and cell phones) running the most updated version of applicable software and plugins. Shareholders should ensure that they have a strong internet connection wherever they intend to participate in the Annual Meeting. Shareholders should also give themselves plenty of time to log in and ensure that they can hear streaming audio prior to the start of the Annual Meeting.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to target a better now.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

INVESTOR RELATIONS AND MEDIA

ImmunoGen

Courtney O’Konek

781-895-0600

[email protected]

OR

FTI Consulting

Robert Stanislaro

212-850-5657

[email protected]